QLGN QUALIGEN THERAPEUTICS INC Investments/Divestments 8-K Filing 2024 - License Agreement with Pan-RAS Holdings, Inc. Qualigen Therapeutics, Inc. entered into a License and Sublicense Agreement with Pan-RAS Holdings, Inc. for the out-license of their renin-angiotensin system inhibitors (RAS) drug development program.Get access to all SEC 8-K filings of the QUALIGEN THERAPEUTICS INC